JP2022545253A - 治療用コンジュゲート - Google Patents

治療用コンジュゲート Download PDF

Info

Publication number
JP2022545253A
JP2022545253A JP2022511190A JP2022511190A JP2022545253A JP 2022545253 A JP2022545253 A JP 2022545253A JP 2022511190 A JP2022511190 A JP 2022511190A JP 2022511190 A JP2022511190 A JP 2022511190A JP 2022545253 A JP2022545253 A JP 2022545253A
Authority
JP
Japan
Prior art keywords
conjugate
use according
asparaginase
coli
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022511190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545253A5 (https=
Inventor
ジェルヴェ，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Porton Biopharma Ltd
Original Assignee
Porton Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Porton Biopharma Ltd filed Critical Porton Biopharma Ltd
Publication of JP2022545253A publication Critical patent/JP2022545253A/ja
Publication of JP2022545253A5 publication Critical patent/JP2022545253A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022511190A 2019-08-21 2020-08-21 治療用コンジュゲート Pending JP2022545253A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1912020.3 2019-08-21
GBGB1912020.3A GB201912020D0 (en) 2019-08-21 2019-08-21 Therapeutic Conjugate
PCT/GB2020/052022 WO2021032997A1 (en) 2019-08-21 2020-08-21 Therapeutic conjugate

Publications (2)

Publication Number Publication Date
JP2022545253A true JP2022545253A (ja) 2022-10-26
JP2022545253A5 JP2022545253A5 (https=) 2023-08-29

Family

ID=68099464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022511190A Pending JP2022545253A (ja) 2019-08-21 2020-08-21 治療用コンジュゲート

Country Status (11)

Country Link
US (1) US20220331411A1 (https=)
EP (2) EP4017525A1 (https=)
JP (1) JP2022545253A (https=)
KR (1) KR20220050934A (https=)
CN (1) CN114450029A (https=)
AU (1) AU2020332081A1 (https=)
BR (1) BR112022003126A2 (https=)
CA (1) CA3151718A1 (https=)
GB (1) GB201912020D0 (https=)
IL (1) IL290747A (https=)
WO (1) WO2021032997A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3156066A1 (en) 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase
WO2022211829A1 (en) * 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019109018A1 (en) * 2017-11-30 2019-06-06 Jazz Pharmaceuticals Ireland Ltd. Methods of treatment with asparaginase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57077B2 (sr) * 2009-07-06 2023-06-30 Jazz Pharmaceuticals Ii Sas Pegilovana l-asparaginaza
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
EP3701036A4 (en) * 2017-10-27 2021-09-01 Pfenex Inc. PROCESS FOR PRODUCING ASPARAGINASE OF E. COLI
JP7784804B2 (ja) * 2017-10-27 2025-12-12 フェネックス インク． 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019109018A1 (en) * 2017-11-30 2019-06-06 Jazz Pharmaceuticals Ireland Ltd. Methods of treatment with asparaginase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 120, [21], JPN6024038377, 2012, pages 2571, ISSN: 0005557676 *
JAZZ PHARMACEUTICALS ADVANCES RECOMBINANT CRISANTASPASE DEVELOPMENT PROGRAM, JPN6024038376, ISSN: 0005557675 *

Also Published As

Publication number Publication date
EP4368251A2 (en) 2024-05-15
KR20220050934A (ko) 2022-04-25
CA3151718A1 (en) 2021-02-25
IL290747A (en) 2022-04-01
EP4017525A1 (en) 2022-06-29
BR112022003126A2 (pt) 2022-05-17
AU2020332081A1 (en) 2022-03-10
GB201912020D0 (en) 2019-10-02
WO2021032997A1 (en) 2021-02-25
CN114450029A (zh) 2022-05-06
US20220331411A1 (en) 2022-10-20
EP4368251A3 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
Dalvie et al. Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
JP6014956B2 (ja) ペグ化されたｌ−アスパラギナーゼ
JP7797441B2 (ja) ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒
US10174302B1 (en) Modified L-asparaginase
IL271504B2 (en) Modified l-asparaginase
JP2012531893A (ja) アルギナーゼ製剤および方法
EP3418383A1 (en) Modified l-asparaginase
CN110520527A (zh) 新型尼古丁降解酶变体
TW202222821A (zh) 用於預防及/或治療covid-19之組合物及方法
US20150376238A1 (en) Polypeptides for Treating and/or Limiting Influenza Infection
JP2022545253A (ja) 治療用コンジュゲート
JP2025170039A (ja) アミノ酸枯渇治療のための組成物の使用方法
Hansen et al. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice
CN121443319A (zh) 尿酸酶变体及其使用方法
BRPI0714380A2 (pt) composiÇÕes anticocaÍna e tratamento
US20230106353A1 (en) System for covalently linking proteins
Ben David et al. The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo
HK40111417A (en) Therapeutic conjugate
US9617325B2 (en) Treatment of IgE-mediated disease
Ramirez-Paz et al. Site-specific PEGylation crosslinking of L-asparaginase subunits to improve its therapeutic efficiency
JP2024512784A (ja) 組換えｌ－アスパラギナーゼの用法及び用量
US20210121544A1 (en) Polypeptide with Asparaginase Activity, Expression Cassette, Expression Vector, Host Cell, Pharmaceutical Composition, Methods for Producing a Polypeptide with Asparaginase Activity and for Preventing or Treating Cancer, and Use of a Polypeptide
Chong Development of amino acid depleting enzyme for the treatment of cancer
CN118516331A (zh) 聚乙二醇修饰的有机磷水解酶及其制备方法和应用
HK1173092B (en) Pegylated l-asparaginase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230821

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250325